Auto-Injector Market

Auto-Injector Market Segmentation by Type (Disposable Auto-Injector, and Reusable Auto-Injector); by Route of Administration (Subcutaneous, and Intramuscular); by Drug Type (Epinephrine, Insulin, Rebif ); by Application (Rheumatoid Arthritis, Anaphylaxis, Diabetes, Multiple Sclerosis, Psoriasis, and Others); by Demography (Pediatric, Adults, & Geriatric); by Distribution Channel (Hospital, Retail, & Online Pharmacies); and by End-User – Global Demand Analysis & Opportunity Outlook 2020-2030

Buy Now
Report ID: 3511 | Published On: Apr 07, 2022

Preview Analysis

Request Insights
Inflation and Looming Recession to Haunt Businesses:

In 2022 & 2023, market players expected to sail in rough waters; might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain. Further, U.S. economy is expected to grow merely by 3% in 2022. Purchasing power in the country is expected to fell nearly by 2.5%.
On the other hand, European countries to see the worst coming in the form of energy crisis especially in upcoming winters!! Right after COVID-19, inflation has started gripping the economies across the globe. Higher than anticipated inflation, especially in western world had raised concerns for national banks and financial institutions to control the economic loss and safeguard the interest of the businesses. Increased interest rates, strong USD inflated oil prices, looming prices for gas and energy resources due to Ukraine-Russia conflict, China economic slowdown (~4% in 2022) disrupting the production and global supply chain and other factors would impact each industry negatively.


In The News

  • November 19, 2019: Antares Pharma, Inc. announced that it has entered into a global development agreement with Idorsia Pharmaceuticals Ltd. for developing a novel drug-device product that would combine Idorsia’s P2Y12 receptor antagonist, selatogrel, with the subcutaneous auto injector of Antares, QuickShot.


GlobalAuto-Injector Market Highlights Over 2020 - 2030

The global auto-injector market is estimated to garner a revenue of USD 11354.6 Million by the end of 2030, by growing at a CAGR of 13.9% over the forecast period, i.e., 2021 – 2030. Further, in the year 2020, the market garnered a revenue of USD 3117.4 Million. The growth of the market can primarily be attributed to the increasing prevalence of allergies worldwide, such as anaphylaxis, along with the increasing cases of diabetes, which is driving the need for auto-injectors for injecting drugs to treat these diseases. According to the statistics by the Asthma and Allergy Foundation of America (AAFA), in the United States, allergic conditions are one of the most common health issues that affects both adult and children. It also stated that every year, it had been estimated that anaphylaxis to food resulted in 30,000 emergency room visits. On the other hand, according to the statistics by the International Diabetes Foundation (IDF), by the end of 2045, adults living with diabetes is expected to touch 700 Million.

Auto-Injector Market Graph

Get more information on this reportDownload Sample PDF

Anaphylaxis, which is a severe and sometimes a sudden allergic reaction, is life-threatening and requires immediate emergency response. The patients, who are at risk for anaphylaxis, are commonly prescribed epinephrine auto injector (EAI), which is known to be an effective solution for the management of the disease. On the other hand, people suffering from diabetes, are required to inject insulin almost on a daily basis, which is anticipated to drive the need for auto-injectors. Such factors are projected to drive the growth of the global auto-injectors market during the forecast period. 


Global Auto-Injector Market Regional Synopsis

Regionally, the global auto-injector market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is anticipated to garner the largest market revenue of USD 4404.5 Million by the end of 2030, and further hold the highest market share during the forecast period. The growth of the market in the region can primarily be attributed to the increasing awareness for allergic and diabetes diseases, which is driving the need for auto-injectors. According to the statistics by the Allergy & Asthma Network, between 1.6% and 5.1% of the population of the United States have experiences anaphylaxis. The market in the region is segmented by country into the United States and Canada. Out of the market in these countries, the market in the United States is projected to hold the highest market share during the forecast period, while the market in Canada is anticipated to grow with the highest CAGR of 14.2% during the forecast period.

The auto-injectors market in Europe is anticipated to hold the second-leading market share during the forecast period and further attain a revenue of USD 4008.2 Million by the end of 2030, up from USD 1084.2 Million in 2020. The market in the region is segmented by country into the United Kingdom, Germany, Italy, France, Spain, Russia, Netherlands, and the Rest of Europe. Out of the market in these countries, the market in Germany is projected to attain the largest revenue of USD 846.1 Million by the end of 2030, and is further anticipated to grow with a CAGR of 14.3% during the forecast period.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).


Growth Drivers and Challenges Impacting the Growth of the Global Auto-Injector Market

Growth Drivers

  • Increasing Prevalence of Anaphylaxis
  • Growing Demand for Auto-Injectors Amongst Diabetic Patients

Challenges

  • Availability of Low-Cost Alternatives
  • High Price of the Injecting Device


Auto-Injector Market Graph
Get more information on this report: Request Sample PDF

Global Auto-Injector Market Segmentation Synopsis

The global auto-injector market is segmented by type into disposable auto-injector, and reusable auto-injector, out of which, the disposable auto-injector segment is projected to garner the highest market share by the end of 2030 and also grow with the highest CAGR of 14% during the forecast period. Further, on the basis of route of administration, the market is segmented into subcutaneous, and intramuscular, out of which, the subcutaneous segment is projected to grow with the highest CAGR of 14.1% during the forecast period. By drug type, the market is segmented into epinephrine, insulin, Rebif, and others. Out of these, the epinephrine segment registered the largest revenue of USD 857.2 Million in the year 2020, and is further expected to touch USD 3230.8 Million by the end of 2030. The global auto-injector market is further segmented on the basis of application into rheumatoid arthritis, anaphylaxis, diabetes, multiple sclerosis, psoriasis, and others, out of which, the diabetes segment is projected to grow with the highest CAGR of 17.5% during the forecast period. On the basis of demography, the market is segmented into pediatric, adults, and geriatric, out of which, the geriatric segment is anticipated to attain the largest revenue of USD 5368.6 Million by the end of 2030 and grow with the highest CAGR of 14.7% during the forecast period. Further, on the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Amongst these segments, the retail pharmacies segment is projected to register the largest revenue of USD 5865.8 Million by the end of 2030. By end-user, the market is segmented into hospital & clinics, home care settings, and ambulatory surgical centers, out of which, the home care settings segment is projected to grow with the highest CAGR of 14.2% during the forecast period and further attain the largest revenue of USD 7496.3 Million by the end of 2030.


Key Companies Dominating the Market

Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global auto-injector market that are included in our report are Pfizer Inc., BD, Adamis Pharmaceuticals Corporation, Biogen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Antares Pharma, Inc., Sanofi S.A., Ypsomed AG, SHL Medical AG, and others.


Key Questions Answered in the Report

1) What are the major factors driving the growth of the auto-injector market?

Ans: The growing prevalence of anaphylaxis and diabetes amongst individuals worldwide is one of the major factors anticipated to drive the market growth in the coming years.

2) What would be the CAGR of auto-injector market over the forecast period?

Ans: The market is anticipated to attain a CAGR of 13.9% over the forecast period, i.e., 2021-2030.

3) What are the challenges affecting the auto-injector market growth?

Ans: The availability of low-cost alternatives is one of the major factors estimated to hamper the market growth.

4) Which region will provide more business opportunities for growth of auto-injector market in future?

Ans: The market in Europe is projected to display significant business opportunities in the near future.

5) Who are the major players dominating the auto-injector market?

Ans: The major players in the market are Pfizer Inc., BD, Adamis Pharmaceuticals Corporation, Biogen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Antares Pharma, Inc., Sanofi S.A., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the auto-injector market?

Ans: The market is segmented by type, route of administration, drug type, application, demography, distribution channel, end-user, and by region.

8) Which segment captures the largest market size in type segment in the auto-injector market?

Ans: The disposable auto-injector segment is anticipated to grow with the highest CAGR of 14% during the forecast period and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

Submit RFP    Buy Now Download Research Report Sample